Investing.com - Mesoblast reported on Tuesday fourth quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Mesoblast announced earnings per share of $-0.1 on revenue of $2.66M. Analysts polled by Investing.com anticipated EPS of $-0.1025 on revenue of $7.59M.
Mesoblast shares are down 43.13% from the beginning of the year and are trading at $2.730 , down-from-52-week-high.They are under-performing the Nasdaq which is down 24.04% from the start of the year.
Mesoblast follows other major Healthcare sector earnings this month
Mesoblast's report follows an earnings missed by Eli Lilly on Thursday, August 4, 2022, who reported EPS of $1.25 on revenue of $6.49B, compared to forecasts EPS of $1.7 on revenue of $6.85B.
Novo Nordisk ADR had missed expectations on Thursday, August 4, 2022 with second quarter EPS of $0.7976 on revenue of $5.62B, compared to forecast for EPS of $0.8198 on revenue of $5.73B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar